RPWA
BMRN icon

Regent Peak Wealth Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Regent Peak Wealth Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-118
Closed -$10K – 250
2020
Q4 		$10K Buy
+118
New +$9.36K ﹤0.01% 557

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Regent Peak Wealth Advisors's BMRN Position: Q1 2021 in Review

Regent Peak Wealth Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2021, closing a stake of 118 shares — an estimated $10K sold.

Regent Peak Wealth Advisors first reported a position in BMRN in Q4 2020 and held it in 1 quarter. The position peaked at $10K in Q4 2020. 530 funds tracked by Wall St. Rank hold BMRN as of Q1 2021.

  • Regent Peak Wealth Advisors reported no remaining BioMarin Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Regent Peak Wealth Advisors sold 118 BioMarin Pharmaceuticals shares in Q1 2021, an estimated $10K.
  • Regent Peak Wealth Advisors first reported a position in BioMarin Pharmaceuticals in Q4 2020 and held it in 1 quarter.
  • Regent Peak Wealth Advisors's BioMarin Pharmaceuticals position peaked at $10K in Q4 2020.
  • 530 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2021.

Based on Regent Peak Wealth Advisors's 13F filing for Q1 2021, filed 28 Apr 2021.